Biology of Blood and Marrow Transplantation
Volume 16, Issue 1, Supplement , Pages S48-S56 , January 2010

Hematopoietic Cell Transplantation for Autoimmune Disease: Updates from Europe and the United States

  • Keith M. Sullivan

      Affiliations

    • Division of Cellular Therapy, Duke University Medical Center, Durham, North Carolina
    • Corresponding Author InformationCorrespondence and reprint requests: Keith M. Sullivan, MD, Division of Cellular Therapy, Duke University Medical Center, Durham, NC 27708.
    • ,
  • Paolo Muraro

      Affiliations

    • Division of Neuroscience and Mental Health, Imperial College London, London, United Kingdom
    • ,
  • Alan Tyndall

      Affiliations

    • Department of Rheumatology, University of Basel, Switzerland, on behalf of the European League Against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT)

References 

  1. Ikehara S, Good RA, Nakamura T, et al. Rationale for bone marrow transplantation in the treatment of autoimmune diseases. Proc Natl Acad Sci USA. 1985;82:2483–2487
  2. van Bekkum DW, Bohre EP, Houben PF, Knaan-Shanzer S. Regression of adjuvant-induced arthritis in rats following bone marrow transplantation. Proc Natl Acad Sci USA. 1989;86:10090–10094
  3. Nelson JL, Torrez R, Louie FM, Choe OS, Storb R, Sullivan KM. Pre-existing autoimmune disease in patients with longterm survival after allogeneic bone marrow transplantation. J Rheum. 1997;24(Suppl 48):23–29
  4. Thomas ED. Pros and cons of stem cell transplantation for autoimmune disease. J Rheum. 1997;24(Suppl 48):100–102
  5. Shlomchik MJ, Craft JE, Mamula MJ. From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol. 2001;1:147–153
  6. van Bekkum DW. Stem cell transplantation in experimental models of autoimmune disease. J Clin Immunol. 2000;20:10–16
  7. Karussis DM, Slavin S, Lehmann D, Mizrachi-Koll R, Abramsky O, Ben-Nun A. Prevention of experimental autoimmune encephalomyelitis and induction of tolerance with acute immunosuppression followed by syngeneic bone marrow transplantation. J Immunol. 1992;148:1693–1698
  8. Cassiani-Ingoni R, Muraro PA, Magnus T, et al. Disease progression after bone marrow transplantation in a model of multiple sclerosis is associated with chronic microglial and glial progenitor response. J Neuropathol Exp Neurol. 2007;66:637–649
  9. Muraro PA, Douek DC, Packer A, et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med. 2005;201:805–816
  10. Snowden JA, Passweg J, Moore JJ, et al. Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. J Rheumatol. 2004;31:482–488
  11. De Kleer IM, Brinkman DM, Ferster A, et al. Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: analysis of clinical effects, mortality, and transplant related morbidity. Ann Rheum Dis. 2004;63:1318–1326
  12. Alexander T, Thiel A, Rosen O, et al. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood. 2009;113:214–223
  13. Brinkman DM, Jol-van der Zijde CM, Ten Dam MM, et al. Resetting the adaptive immune system after autologous stem cell transplantation: lessons from responses to vaccines. J Clin Immunol. 2007;27:647–648
  14. Shevach EM. Regulatory T cells in autoimmmunity. Annu Rev Immunol. 2000;18:423–449
  15. Stephens LA, Mottet C, Mason D, Powrie F. Human CD4(+)CD25(+) thymocytes and peripheral T cells have immune suppressive activity in vitro. Eur J Immunol. 2001;31:1247–1254
  16. Anderson BE, McNiff JM, Matte C, Athanasiadis I, Shlomchik WD, Shlomchik MJ. Recipient CD4+ T cells that survive irradiation regulate chronic graft-versus-host disease. Blood. 2004;104:1565–1573
  17. Herrmann MM, Gaertner S, Stadelmann C, et al. Tolerance induction by bone marrow transplantation in a multiple sclerosis model. Blood. 2005;106:1875–1883
  18. Tyndall A, Gratwohl A. Blood and marrow stem cell transplants in autoimmune disease. A consensus report written on behalf of the European League Against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT). Br J Rheumatol. 1997;36:390–392
  19. Sullivan KM, Furst DE. The evolving role of blood and marrow transplantation for the treatment of autoimmune diseases. J Rheumatol. 1997;24(Suppl 48):1–4
  20. Tamm M, Gratwohl A, Tichelli A, Perruchoud AP, Tyndall A. Autologous haemopoietic stem cell transplantation in a patient with severe pulmonary hypertension complicating connective tissue disease. Ann Rheum Dis. 1996;55:779–780
  21. Gratwohl A, Passweg J, Bocelli-Tyndall C, Fassas A, van Laar JM, Farge D, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplant. 2005;35:869–879
  22. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993;36:1681–1690
  23. Fleming JN, Nash RA, McLeod DO, Fiorentino DF, Shulman HM, Connolly MK, et al. Capillary regeneration in scleroderma: stem cell therapy reverses phenotype?. PLoS ONE. 2008;3:e1452
  24. Mancardi G, Saccardi R. Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol. 2008;7:626–636
  25. Nash RA, McSweeney PA, Crofford LJ, et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-tern follow-up of the US multicenter pilot study. Blood. 2007;110:1386–1396
  26. Burt RK, Traynor A, Statkute L, et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erhthematosus. JAMA. 2006;295:527–535
  27. Nash RA, Bowen JD, McSweeney PA, et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood. 2003;102:2364–2372
  28. Burt RK, Loh Y, Cohen B, et al. Autologous nonmyeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol. 2009;8:244–253
  29. Griffith LM, Pavletic SZ, Tyndall A, et al. Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Disease and National Cancer Institute-sponsored international workshop, Bethesda, MD, March 12 and 13, 2005. Biol Blood Marrow Transplant. 2005;11:862–870
  30. Dilts DM, Sandler A, Cheng S, et al. Development of clinical trials in a cooperative group setting: the Eastern Cooperative Oncology Group. Clin Cancer Res. 2008;14:342–333
  31. Burt RK, Marmont A, Arnold R, et al. Development of a phase III trial of hematopoietic stem cell transplantation for systemic lupus erythematosus. Bone Marrow Transplant. 2003;32:S49–S51
  32. Lara PN, Paterniti DA, Chiechi C, et al. Evaluation of factors affecting awareness and willingness to participate in cancer clinical trials. J Clin Oncol. 2005;23:9282–9289
  33. Casalino LO, Nicholson S, Gans DN, et al. What does it cost physician practices to interact with health insurance plans?. Health Affairs. 2009;28:w533–w543
  34. Comis RL, Miller JD, Aldige CR, Krebs Stoval E. Public attitudes toward participation in cancer clinical trials. J Clin Oncol. 2003;21:830–835
  35. Peters Wp, Rogers MC. Variation in approval by insurance companies of coverage for autologous bone marrow transplantation for breast cancer. N Engl J Med. 1994;330:473–477
  36. Light DW. Life, death and the insurance companies. N Engl J Med. 1994;330:498–500
  37. Tashkin DP, Elashofff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354:2655–2666
  38. Technology Assessment. Horizon Scan: To What Extent Do Changes in Third Party Payment Affect Clinical Trials and the Evidence Base?. Rockville, MD: Agency for Healthcare Research and Quality; August 28, 2009;http://www.cms.hhs.gov/determinationprocess/downloads/id67aTA.pdf
  39. Dickinson AM. Biobanks and registries for HSCT research: potential for future individualized medicine. Int J Immunogenet. 2006;33:153–154

 Financial disclosure: See Acknowledgments on page S55.

PII: S1083-8791(09)00516-3

doi: 10.1016/j.bbmt.2009.10.034

Biology of Blood and Marrow Transplantation
Volume 16, Issue 1, Supplement , Pages S48-S56 , January 2010

Article Tools

* Image Usage & Resolution